World Investment Advisors LLC Buys 54,162 Shares of Johnson & Johnson (NYSE:JNJ)

World Investment Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 189.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 82,736 shares of the company's stock after buying an additional 54,162 shares during the quarter. World Investment Advisors LLC's holdings in Johnson & Johnson were worth $13,408,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Sculati Wealth Management LLC grew its stake in Johnson & Johnson by 0.5% during the 3rd quarter. Sculati Wealth Management LLC now owns 16,334 shares of the company's stock valued at $2,584,000 after acquiring an additional 74 shares in the last quarter. Anchor Investment Management LLC increased its stake in Johnson & Johnson by 2.0% in the 3rd quarter. Anchor Investment Management LLC now owns 90,873 shares of the company's stock valued at $14,727,000 after buying an additional 1,761 shares during the period. Tudor Financial Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $888,000. Te Ahumairangi Investment Management Ltd grew its holdings in shares of Johnson & Johnson by 10.1% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock valued at $8,180,000 after acquiring an additional 4,640 shares in the last quarter. Finally, Passumpsic Savings Bank acquired a new position in shares of Johnson & Johnson in the third quarter worth $262,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ traded down $0.41 during mid-day trading on Thursday, hitting $146.23. The company's stock had a trading volume of 6,174,458 shares, compared to its average volume of 7,118,662. The stock's 50-day moving average is $157.29 and its two-hundred day moving average is $156.35. The firm has a market capitalization of $352.07 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the firm posted $2.66 EPS. The business's revenue was up 5.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on JNJ. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 14th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective on the stock. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $174.73.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.